Ten Years After Mutation Testing for Lynch Syndrome: Cancer Incidence and Outcome in Mutation-Positive and Mutation-Negative Family Members
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Purpose: Colonoscopies with polypectomies and endometrial biopsies with transvaginal ultrasonography, repeated at 2- to 3-year intervals, are performed for prevention or early detection of cancer in patients with DNA mismatch repair gene mutation causing Lynch syndrome. The long-term effectiveness of surveillance was evaluated in Lynch syndrome family members tested approximately 10 years ago. Materials and Methods: Cancer incidence and survival were determined after an 11.5-year follow-up in 242 mutation-positive and 367 mutation-negative participants. These participants in 57 Lynch syndrome families with 14 different mutations were at 50% risk. The median age was 36 years (range, 18 to 72 years) in mutation carriers and 42 years (range, 18 to 72 years) in mutation-negative participants, and none had had cancer of the Lynch syndrome type. Results: Compliance was 95.9% for the colonic surveillance and 97.1% for the gynecologic surveillance. Colorectal cancer (CRC) occurred in 30 mutation-positive participants, and 74 participants had adenomas removed. Three patients died of CRC. Endometrial cancer (EC) occurred in 19 of 103 women at risk, and 48 women had prophylactic hysterectomy. Six of 112 women at risk had ovarian cancer. The overall cancer risk ratio (RR) in mutation carriers was 5.80 (95% CI, 3.4 to 9.5). Cancer mortality rate (RR = 2.28; 95% CI, 0.82 to 6.31) and overall death rate (RR = 1.26; 95% CI, 0.65 to 2.46) were not significantly increased. Conclusion: Long-term compliance in surveillance for CRC and EC exceeded 95% in Lynch syndrome. All CRC deaths were not prevented as a result of noncompliance or missed lesions. Still, after 10 years of surveillance, no significant increase in mortality had occurred compared with mutation-negative relatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, H. T., & de la Chapelle, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012242 · Cited by 2,203
Järvinen, H. J., Aarnio, M., Mustonen, H., Aktan–Collan, K., Aaltonen, L. A., Peltomäki, P., Chapelle, A. D. L., & Mecklin, J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70168-5 · Cited by 1,337
Self-citationCancer risk in mutation carriers of DNA-mismatch-repair genes
Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., Peltom�ki, P., Mecklin, J.-P., & J�rvinen, H. J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990412)81:2<214::aid-ijc8>3.0.co;2-l · Cited by 1,278
Self-citationProphylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome
Schmeler, K. M., Lynch, H. T., Chen, L.-M., Munsell, M. F., Soliman, P. T., Clark, M. B., Daniels, M. S., White, K. G., Boyd-Rogers, S. G., Conrad, P. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052627 · Cited by 794
The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome
Watson, P., Vasen, H. F. A., Mecklin, J., Bernstein, I., Aarnio, M., Järvinen, H. J., Myrhøj, T., Sunde, L., Wijnen, J. T., & Lynch, H. T. (2008) · International Journal of Cancer · doi:10.1002/ijc.23508 · Cited by 596
Self-citationGuidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
Vasen, H. F. A., Möslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., Burn, J., Capella, G., Engel, C., Frayling, I., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.048991 · Cited by 554
Self-citationPopulation-Based Molecular Detection of Hereditary Nonpolyposis Colorectal Cancer
Salovaara, R., Loukola, A., Kristo, P., Kääriäinen, H., Ahtola, H., Eskelinen, M., Härkönen, N., Julkunen, R., Kangas, E., Ojala, S., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2193 · Cited by 516
Self-citationDecrease in Mortality in Lynch Syndrome Families Because of Surveillance
de Jong, A. E., Hendriks, Y. M. C., Kleibeuker, J. H., de Boer, S. Y., Cats, A., Griffioen, G., Nagengast, F. M., Nelis, F. G., Rookus, M. A., & Vasen, H. F. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.032 · Cited by 302
Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801297 · Cited by 300
Self-citationSurveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome
Renkonen‐Sinisalo, L., Bützow, R., Leminen, A., Lehtovirta, P., Mecklin, J., & Järvinen, H. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22446 · Cited by 195
Self-citation
Cited by
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Cohn, D., Crispens, M. A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0006 · Cited by 643
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Chu, C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0006 · Cited by 568
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.001 · Cited by 558
Møller, P., Seppälä, T., Bernstein, I., Holinski-Feder, E., Sala, P., Evans, D. G., Lindblom, A., Macrae, F., Blanco, I., Sijmons, R., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309675 · Cited by 548
Self-citationGiardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, R. C., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.186 · Cited by 483
InSiGHT, O. B. O., Thompson, B. A., Spurdle, A. B., Plazzer, J.-P., Greenblatt, M. S., Akagi, K., Al-Mulla, F., Bapat, B., Bernstein, I., Capellá, G., et al. (2014) · Nature Genetics · doi:10.1038/ng.2854 · Cited by 467
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
van de Velde, C. J. H., Boelens, P. G., Borras, J. M., Coebergh, J.-W., Cervantes, A., Blomqvist, L., Beets-Tan, R. G. H., van den Broek, C. B. M., Brown, G., Van Cutsem, E., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.048 · Cited by 404
Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., Ford, J., Elkin, E., & Phillips, K. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-2-201107190-00002 · Cited by 340
Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd666c · Cited by 292
Provenzale, D., Gupta, S., Ahnen, D. J., Bray, T., Cannon, J. A., Cooper, G., David, D. S., Early, D. S., Erwin, D., Ford, J. M., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0108 · Cited by 255
Weitzel, J. N., Blazer, K. R., MacDonald, D. J., Culver, J. O., & Offit, K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20128 · Cited by 249
“Similarly, colonoscopic screening has proven efficacy in the early detection and/or prevention of colon cancer in patients with Lynch syndrome.(164) Even before these studies demonstrated decreased mortality, the available body of evidence for the relative efficacy of interventions following genetic risk assessment fo…”
BackgroundRelevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
Funkhouser, W. K., Lubin, I. M., Monzon, F. A., Zehnbauer, B. A., Evans, J. P., Ogino, S., & Nowak, J. A. (2012) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.11.001 · Cited by 189
The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?
Hampel, H., & de la Chapelle, A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0345 · Cited by 170
Pancreatic cancer in Lynch syndrome patients
Bujanda, L., & Herreros-Villanueva, M. (2017) · Journal of Cancer · doi:10.7150/jca.20750 · Cited by 57
Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention
Kassem, N., Stout, L. A., Hunter, C., Schneider, B., & Radovich, M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00278 · Cited by 5
Metadata
- Authors
- Järvinen, H. J., Renkonen-Sinisalo, L., Aktán-Collán, K., Peltomäki, P., Aaltonen, L. A., & Mecklin, J.-P.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-01
- Volume
- 27
- Issue
- 28
- Pages
- 4793-4797
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113677863
- Cited by
- 282
- References
- 15
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.